+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07855211

Evaluating Safety, Tolerability, and Effects of Intrathecal BIIB147 Compared to Placebo in Adults with Amyotrophic Lateral Sclerosis with an Open-Label Extension

Led by Biogen · Updated on 2026-10-26

69

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying BIIB147 in adults with amyotrophic lateral sclerosis ALS, a rare and progressive disease that damages motor neurons controlling muscle movement. This first-in-human trial aims to evaluate the safety and tolerability of BIIB147, as well as how the body processes the drug and what dose might be appropriate. The study also investigates the drugs effects on disease progression, survival, and biomarkers like neurofilament light chain protein. Participants will be randomly assigned to receive one of several doses of BIIB147 or a placebo, administered intrathecally via lumbar puncture. The main treatment periods vary from 12 to 20 weeks depending on the dose group. After completing this phase, participants enter a 4-week blinded loading-dose period followed by an open-label extension where all receive BIIB147 for up to 340 weeks. The study drug and placebo are given through spinal injections under double-blind conditions. During the trial, participants will have regular clinic visits and phone calls for health assessments, including brain and nerve function, breathing, muscle strength, and vital signs. Blood and urine samples will be collected, and participants will complete questionnaires about their health and daily living. Some participants may continue in a long-term extension phase lasting up to 6 years, followed by a safety follow-up. Overall, each participant may be involved in the study for 8 years or more while researchers monitor adverse events, drug levels, disease progression, and survival outcomes.

CONDITIONS

Brief Title

A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)

Research Team

U

US Biogen Clinical Trial Center

G

Global Biogen Clinical Trial Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here